Rethinking furosemide use for infants with bronchopulmonary dysplasia. Pediatr Pulmonol 2020 May;55(5):1100-1103
Date
03/17/2020Pubmed ID
32176837DOI
10.1002/ppul.24722Scopus ID
2-s2.0-85081729340 (requires institutional sign-in at Scopus site) 10 CitationsAbstract
Diuretics are commonly administered to infants with bronchopulmonary dysplasia (BPD) to improve respiratory function despite the absence of prospective data demonstrating long term benefits. While many potentially adverse effects of furosemide are known to clinicians, its direct and indirect impact on multiple pathophysiological processes need to be understood. While furosemide likely has a role in the management of infants with BPD, clinicians are encouraged to recognize these potential complications associated with furosemide administration. Specifically, a deeper understanding of the impact of diuretics on sodium metabolism neurohumoral regulation of cardiopulmonary physiology is required.
Author List
Segar JLAuthor
Jeffrey L. Segar MD Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Bronchopulmonary DysplasiaChronic Disease
Furosemide
Hospitalization
Humans
Infant, Newborn
Infant, Premature
Intensive Care Units, Neonatal
Prospective Studies